Keywords: update, rebif, avonex, head-to-head, ms, study, serono

Update - Rebif and Avonex head-to-head in MS study

Article | 09 May 2001

Print This

Serono of Switzerland may be able to launch its multiple sclerosis drugRebif (interferon beta-1a) in the $1 billion US market ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in